Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Iacoboni

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Leukemia|September 1, 1987
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemiaL Danhauser, W Plunkett, J Liliemark, et al.
Seminars in Oncology|June 1, 1985
Pharmacologically directed ara-C therapy for refractory leukemiaW Plunkett, S Iacoboni, E Estey, et al.
The American Journal of Medicine|September 1, 1986
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemiaH M Kantarjian, E H Estey, W Plunkett, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Leukemia|September 1, 1987
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemiaL Danhauser, W Plunkett, J Liliemark, et al.
Seminars in Oncology|June 1, 1985
Pharmacologically directed ara-C therapy for refractory leukemiaW Plunkett, S Iacoboni, E Estey, et al.
The American Journal of Medicine|September 1, 1986
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemiaH M Kantarjian, E H Estey, W Plunkett, et al.
Pageof 1